Uploaded July 2023 | Updated September 2026, 1 week ago

---

📣 Announcing the preclinical candidate for an inhalation solution of ISM001-055, the first anti-fibrotic small molecule inhibitor developed leveraging Insilico's proprietary AI drug discovery platform Pharma.AI for the treatment of the chronic progressive lung disease Idiopathic Pulmonary Fibrosis (IPF).



● With promising preclinical results, Insilico is proceeding with IND filing as the first AI drug discovery company to venture into nebulized formulations.


● Potential advantages for the inhalation solution include a smaller effective dose, larger safety window, and reduced side effects.


● As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) profiles, and no local or systemic toxicity observed.


Learn more: eurekalert.org/news-releases/996263